Given the absence of trials testing IL-1β inhibitors in combination with TKIs, future studies should evaluate this strategy in genetically defined NSCLC subsets to determine whether dual targeting of oncogenic signaling and inflammation can improve outcomes. Here, IL1B is linked to non-small cell lung carcinoma.